Merck (MRK) EBIT (QoQ) (2009 - 2026)
Powered by 
Analysis
Merck (MRK) EBIT (QoQ) (2009 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn |
| 10 | Neurocrine Biosciences | 15.82 Bn | 15.43 Bn | 935.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 82.80% |
| Mar 31, 2026 | -144.75% |
| Dec 31, 2025 | 16.61% |
| Sep 30, 2025 | 30.35% |
| Jun 30, 2025 | -14.93% |
| Mar 31, 2025 | 36.56% |
| Dec 31, 2024 | 9.39% |
| Sep 30, 2024 | -35.05% |
| Jun 30, 2024 | 7.29% |
| Mar 31, 2024 | 161.09% |
| Dec 31, 2023 | -62.43% |
| Sep 30, 2023 | 211.29% |
| Jun 30, 2023 | -238.09% |
| Mar 31, 2023 | 8.76% |
| Dec 31, 2022 | -14.31% |
| Sep 30, 2022 | -18.54% |
| Jun 30, 2022 | -11.56% |
| Mar 31, 2022 | 55.78% |
| Dec 31, 2021 | -25.77% |
| Sep 30, 2021 | 198.39% |